BioRestorative Therapies
BRTXBRTX · Stock Price
Historical price data
Overview
BioRestorative Therapies is a micro-cap biotech focused on developing regenerative therapies using adult stem cells to address conditions with high unmet medical need. Its core strategy balances a high-risk, high-reward clinical pipeline targeting chronic pain and metabolic disorders with a commercial cosmeceutical division for near-term revenue. Key achievements include the ongoing Phase 2 trial for BRTX-100 in chronic lumbar disc disease and the establishment of its scientific platform. The company's mission is to leverage the body's intrinsic repair mechanisms to improve patient outcomes in large, underserved markets.
Technology Platform
Platform based on the isolation, culture, and therapeutic application of adult stem cells from two sources: bone marrow (for immunomodulation/repair) and brown adipose tissue (for metabolic modulation).
Pipeline
1| Drug | Indication | Stage | Watch |
|---|---|---|---|
| BRTX-100 + Saline | Lumbar Disc Disease | Phase 2 |
Opportunities
Risk Factors
Competitive Landscape
BRTX-100 competes in a crowded chronic pain space against medical devices, pharmaceuticals, and other biologic approaches. ThermoStem is a novel but high-risk entry into the massive metabolic disorder market, competing primarily against advanced pharmacotherapies. The BioCosmeceuticals line operates in a fragmented aesthetic market.